TARSUS PHARMACEUTICALS, INC. Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period
TARSUS PHARMACEUTICALS, INC. (TARS) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period of 0 shares for the 3-month period ending 2024-03-31, per its 10-Q filed 2024-05-08.
Discontinued › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod · last filed 2024-05-08
- TARSUS PHARMACEUTICALS, INC. share-based compensation arrangement by share-based payment award, options, expirations in period for the quarter ending 2024-03-31 was 0.00 shares.
- TARSUS PHARMACEUTICALS, INC. share-based compensation arrangement by share-based payment award, options, expirations in period for fiscal 2023 was 0.00 shares.
- TARSUS PHARMACEUTICALS, INC. share-based compensation arrangement by share-based payment award, options, expirations in period for fiscal 2022 was 0.00 shares.
- TARSUS PHARMACEUTICALS, INC. share-based compensation arrangement by share-based payment award, options, expirations in period for fiscal 2021 was 0.00 shares.
- TARSUS PHARMACEUTICALS, INC. share-based compensation arrangement by share-based payment award, options, expirations in period for fiscal 2020 was 0.00 shares, a 100.00% decline from fiscal 2019.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period 12 month |
|---|---|---|
| 2024-03-31 | 0.00 shares 10-Q · filed 2024-05-08 | |
| 2023-12-31 | 0.00 shares 10-K · filed 2024-02-27 | |
| 2022-12-31 | 0.00 shares 10-K · filed 2024-02-27 | |
| 2021-12-31 | 0.00 shares 10-K · filed 2023-03-17 | |
| 2020-12-31 | 0.00 shares 10-K · filed 2022-03-14 | |
| 2019-12-31 | 785.00 shares 10-K · filed 2021-03-31 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Denali Therapeutics Inc. (DNLI) | United States | $3.274B | -8.04 |
| Relay Therapeutics, Inc. (RLAY) | United States | $3.884B | -14.30 |
| Beam Therapeutics Inc. (BEAM) | United States | $2.549B | -41.51 |
| Greenland Mines Ltd (GRML) | United States | $2.362B | |
| BIOCRYST PHARMACEUTICALS INC (BCRX) | United States | $2.175B | -6.63 |
| ADMA BIOLOGICS, INC. (ADMA) | United States | $2.131B | 11.16 |
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |
| RECURSION PHARMACEUTICALS, INC. (RXRX) | United States | $2.080B | -3.78 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| Adaptive Biotechnologies Corp (ADPT) | United States | $4.719B | -53.43 |